Acta Chir Orthop Traumatol Cech. 2011; 78(6):537-543 | DOI: 10.55095/achot2011/085
Xenogeneic Protein Free Cultivation of Mesenchymal Multipotent Stromal CellsOriginal papers
- 1 Klinika ortopedie dětí a dospělých 2. LF UK a FN Motol, Praha
- 2 1. Interní klinika 1. LF UK, Praha
- 3 Anatomický ústav, 1. LF UK, Praha
PURPOSE OF THE STUDY:
The aim of this study was to compare the standard laboratory method of cultivation of mesenchymal multipotent stromal cells (MSC) and a novel technique of rapid MSC expansion focused on simple clinical use.
MATERIAL AND METHODS:
Bone marrow mononuclear cells of donors were cultured for 14 days by the standard and the new cultivation method. The standard method (STD) was based on an alpha MEM medium supplemented with foetal calf serum (FCS). The new animal protein-free method (CLI) was based on the clinical grade medium CellgroTM, pooled human serum and human recombinant growth factors (EGF, PDGF-BB, M-CSF, FGF-2) supplemented with dexamethasone, insulin and ascorbic acid. The cell product was analyzed by flow cytometry. Furthermore, the cell products of STD and CLI methods were differentiated in vitro, and histochemical and immunohistochemical analyses, electron microscopy and elemental analysis were performed. Some cells were seeded on biodegradable scaffolds, in vivo implanted into immunodeficient mice for 6 weeks and evaluated by histological methods.
RESULTS:
Yields of the CLI method after 14 days of cultivation were 40-fold higher than those obtained by the STD technique (p<0.05). Cell products of both STD and CLI methods fulfilled the criteria of MSC in terms of antigen expression assessed by flow cytometry, as well as osteogenic, chondrogenic and adipogenic in vitro differentiation assays. Moreover, these cells seeded on three-dimensional scaffolds cultured in osteogenic medium produced mineral deposits and a fibrillar extracellular matrix seen with the electron microscope. Deposits examined by element analysis contained calcium and phosphorus at a ratio of 5 to 3, which corresponded to hydroxyapatite. The cell product seeded on biodegradable scaffolds and implanted into immunodeficient mice was able to form a bone-like calcified tissue with blood supply of mouse origin.
DISCUSSION:
The currently used methods of cultivation have certain disadvantages compared to the CLI technique, such as a longer cultivation period, need of primary expansion and reseeding and use of FCS with all its potential risks. High yields of cells obtained by the CLI method in a very short time make the use of cultured cells potentially suitable for an acute trauma management. Other therapeutic non-orthotopic applications of CLI-cultured cells have to be further investigated.
CONCLUSIONS:
The CLI method is unique, rapid, simple and lacking the addition of animal proteins. CLI-cultured cells fulfil the criteria of MSC. The CLI method potentially allows for closed system cultivation in good manufacturing practice (GMP) conditions. It seems to be easily transferable to good clinical practice compared to other protocols and should extend the possibilities of cell therapy and tissue engineering of cartilage and bone. The new method is protected by Czech patent 301 148 and by europian patent EP 1999250 according to Czech and international laws.
Keywords: cell therapy, tissue engineering, multipotent mesenchymal stromal cells, good manufacturing practice, growth factors, human serum
Published: December 1, 2011 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- ABDALLAH, B. M., KASSEM, M.: The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. J. Cell. Physiol., 218: 9-12, 2009.
Go to original source...
Go to PubMed...
- BAKSH, D., DAVIES, J. E., ZANDSTRA, P. W.: Soluble factor cross-talk between human bone marrow-derived hematopoietic and mesenchymal cells enhances in vitro CFU-F and CFU-O growth and reveals heterogeneity in the mesenchymal progenitor cell compartment. Blood, 106: 3012-3019, 2005.
Go to original source...
Go to PubMed...
- CAPLAN, A. I.: Adult mezenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell. Physiol., 213: 341-347, 2007.
Go to original source...
Go to PubMed...
- CHASE, L. G., LAKSHMIPATHY, U., SOLCHAGA, L. A., RAO, M. S., VEMURI, M. C.: A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell. Res. Ther., 1: 8, 2010.
Go to original source...
Go to PubMed...
- CHEN, L. B., JIANG, X. B., YANG, L.: Differentiation of rat marrow mezenchymal stem cells into pancreatic islet beta-cells. World J. Gastroenterol., 10: 3016-3020, 2004.
Go to original source...
Go to PubMed...
- CHOPP, M., LI, Y.: Treatment of neural injury with marrow stromal cells. Lancet Neurol., 1: 92-100, 2002.
Go to original source...
Go to PubMed...
- DOMINICI, M., LE BLANC, K., MUELLER, I., SLAPER-CORTENBACH, I., MARINI, F., KRAUSE, D., DEANS, R., KEATING, A., PROCKOP, D., HORWITZ, E.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8: 315-317, 2006.
Go to original source...
Go to PubMed...
- GRONTHOS, S., SIMMONS, P. J.: The growth factor requirements of STRO-1-positive human bone marrow stromal precursors under serum-deprived conditions in vitro. Blood, 85: 929-940, 1995.
Go to original source...
- HALME, D. G., KESSLER, D. A.: FDA regulation of stem-cell-based therapies. N. Engl. J. Med., 355: 1730-1735, 2006.
Go to original source...
Go to PubMed...
- HERNIGOU, P., POIGNARD, A., BEAUJEAN, F., ROUARD, H.: Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J. Bone Jt Surg., 87A: 1430-1437, 2005.
Go to original source...
- JIN-XIANG, F., XIAOFENG, S., JUN-CHUAN, Q., YAN, G., XUE-GUANG, Z.: Homing efficiency and hematopoietic reconstitution of bone marrow-derived stroma cells expanded by recombinant human macrophage-colony stimulating factor in vitro. Exp. Hematol., 32: 1204-1211, 2004.
Go to original source...
Go to PubMed...
- KITOH, H., KITAKOJI, T., TSUCHIYA, H., KATOH, M., ISHIGURO, N.: Distraction osteogenesis of the lower extremity in patients with achondroplasia/hypochondroplasia treated with transplantation of culture-expanded bone marrow cells and platelet-rich plasma. J. Pediatr. Orthop., 27: 629-634, 2007.
Go to original source...
Go to PubMed...
- KUBIES, D., RYPACEK, F., KOVAROVA, J., LEDNICKY, F.: Microdomain structure in polylactide-block-poly(ethylene oxide) copolymer films. Biomaterials, 21: 529-536, 2000.
Go to original source...
Go to PubMed...
- KUČERA, T., URBAN, K., SOUKUP, T.: Hojení kostních defektů. Ortopedie, 3: 226-231, 2009.
- MACKAY, A. M., BECK, S. C., MURPHY, J.M., BARRY, F. P., CHICHESTER, C. O., PITTENGER, M. F.: Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng., 4: 415-428, 1998.
Go to original source...
Go to PubMed...
- MAKINO, S., FUKUDA, K., MIYOSHI, S., KONISHI, F., KODAMA, H., PAN, J., SANO, M., TAKAHASHI, T., HORI, S., ABE, H., HATA, J., UMEZAWA, A., OGAWA, S.: Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest., 103: 697-705, 1999.
Go to original source...
Go to PubMed...
- PROCKOP, D. J.: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276: 71-74, 1997.
Go to original source...
Go to PubMed...
- SCHALLMOSER, K., BARTMANN, C., ROHDE, E., BORK, S., GUELLY, C., OBENAUF, A. C., REINISCH, A., HORN, P., HO, A. D., STRUNK, D., WAGNER, W.: Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica, 2010.
Go to original source...
- SCHALLMOSER, K., BARTMANN, C., ROHDE, E., REINISCH, A., KASHOFER, K., STADELMEYER, E., DREXLER, C., LANZER, G., LINKESCH, W., STRUNK, D.: Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion, 47: 1436-1446, 2007.
Go to original source...
Go to PubMed...
- SELVAGGI, T. A., WALKER, R. E., FLEISHER, T. A.: Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood, 89: 776-779, 1997.
Go to original source...
- SHAHDADFAR, A., FRONSDAL, K., HAUG, T., REINHOLT, F. P., BRINCHMANN, J. E.: In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cell., 23: 1357-1366, 2005.
Go to original source...
Go to PubMed...
- TSUTSUMI, S., SHIMAZU, A., MIYAZAKI, K., PAN, H., KOIKE, C., YOSHIDA, E., TAKAGISHI, K., KATO, Y.: Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem. Biophys. Res. Commun., 288: 413-419, 2001.
Go to original source...
Go to PubMed...
- UNGER, C., SKOTTMAN, H., BLOMBERG, P., DILBER, M. S., HOVATTA, O.: Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum. Mol. Genet., 17: R48-53, 2008.
Go to original source...
Go to PubMed...
- WAGNER, W., BORK, S., HORN, P., KRUNIC, D., WALENDA, T., DIEHLMANN, A., BENES, V., BLAKE, J., HUBER, F. X., ECKSTEIN, V., BOUKAMP, P., HO, A. D.: Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS One, 4: e5846, 2009.
Go to original source...
Go to PubMed...
- WERNTZ, J. R., LANE, J. M., BURSTEIN, A. H., JUSTIN, R., KLEIN, R., TOMIN, E.: Qualitative and quantitative analysis of orthotopic bone regeneration by marrow. J. Orthop. Res., 14: 85-93, 1996.
Go to original source...
Go to PubMed...
- ZHAO, L. R., DUAN, W. M., REYES, M., KEENE, C. D., VERFAILLIE, C. M., LOW, W. C.: Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp. Neurol., 174: 11-20, 2002.
Go to original source...
Go to PubMed...